Article Text

PDF
THU0482 Gene Expression Profiling of Whole Blood Samples of TRAPS Patients Shows Insight into the Molecular Pathogenesis of TRAPS and Response to Canakinumab Treatment
  1. N. Nirmala1,
  2. R. Torene1,
  3. H. Lachmann2,
  4. L. Obici3,
  5. A. Meini4,
  6. V. Tormey5,
  7. R. Caorsi6,
  8. L. Baeriswyl7,
  9. U. Affentranger7,
  10. S. Starck-Schwertz7,
  11. M. Letzkus7,
  12. N. Hartmann7,
  13. K. Abrams8,
  14. M. Gattorno6
  1. 1Novartis Institutes for Biomedical Research (NIBR), Cambridge, United States
  2. 2Royal Free Hospital, London, United Kingdom
  3. 3Amyloid Centre, IRCCS Policlinico San Matteo, Pavia
  4. 4Pediatric Clinic, Spedali Civili, Brescia, Italy
  5. 5Galway University Hospitals, Galway, Ireland
  6. 6G. Gaslini Institute, Genova, Italy
  7. 7NIBR, Basel, Switzerland
  8. 8Novartis Pharmaceuticals Corporation, New Jersey, United States

Abstract

Background TNF receptor-associated periodic syndrome (TRAPS) is an autoinflammatory disease causing unprovoked fevers, myalgia, abdominal pain, rash, headaches, and, in severe cases, AA amyloidosis. It is an autosomal dominant condition resulting from variants in the TNF super family receptor 1A (TNFRSF1A) gene.1 A hallmark of TRAPS is a huge activation of the inflammatory response in the absence of autoantibodies or antigen-specific T-cells.1 Canakinumab (CAN) is a high-affinity, fully human, selective, anti-IL-1β monoclonal antibody, developed for the treatment of autoinflammatory diseases.2

Objectives To determine whether gene expression in whole blood can support a molecular mechanism for the activity of CAN in TRAPS patients (pts).

Methods Twenty pts with active TRAPS received open-label CAN 150mg sc/month for 4 months in an efficacy and safety study. These pts were assessed at Day 15 for response by physician global assessment (PGA) disease activity scale. Whole blood was collected at baseline, Day 15 and Day 113 from 19 of these pts and 1 sample each from 19 untreated age-matched healthy volunteers for analysis of gene expression levels by microarrays.

Results All 20 pts showed improvements in PGA score (Figure 1-left). Gene expression profiles of these pts were altered by treatment with CAN. Forty-six differentially expressed genes showed a >2-fold change after treatment with expression levels that shifted towards that of healthy volunteers. The disease-causing gene (TNFRSF1A, Figure 1-right), drug target gene (IL-1β), and other inflammation related genes (e.g., MAPK14) were downregulated after treatment and several inflammation related pathways were evident among the differentially expressed genes. Many of the high confidence differentially expressed genes had expression levels that correlated with neutrophil count, however, neutrophil count alone could not account for the expression differences observed.

Figure 1.

Left – Physician's assessment score of TRAPS patients at baseline and after CAN treatment. Higher scores indicate a more severe condition. Right – Gene experssion levels for TNFRSF1A for healthy volunteers (HV) and TRAPS patients for whole blood. Note how expression levels are elevated in TRAPS patients at baseline compared to HV, however, after treatment with CAN, expression levels are comparable to that of HV. Lines connect samples across different visits derived from the same patient.

Conclusions Altogether, the gene expression data support a model in which CAN increases neutrophil apoptosis and reduces pro-inflammatory signals through its inhibition of IL-1β. CAN is able to reverse the overexpression of several genes associated with inflammatory response, including IL-1. Interestingly, IL-1 blockade normalized the overexpression of the disease-causing gene, TNFRSF1A, at the RNA level, suggesting a direct impact on its main pathogenic mechanism.

References

  1. McDermott MF, et al. Cell 1999; 97(1):133–44. 2. Lachmann HJ, et al. J Exp Med.2009; 206(5):1029–36.

Disclosure of Interest : N. Nirmala Employee of: Novartis Institutes of Biomedical Research, R. Torene Employee of: Novartis Institutes of Biomedical Research, H. Lachmann Grant/research support: Novartis, Celtic, L. Obici Consultant for: Consultation fees from Pfizer Pharmaceuticals, A. Meini: None declared, V. Tormey: None declared, R. Caorsi: None declared, L. Baeriswyl Employee of: Novartis Institutes of Biomedical Research, U. Affentranger Employee of: Novartis Institutes of Biomedical Research, S. Starck-Schwertz Employee of: Novartis Institutes of Biomedical Research, M. Letzkus Employee of: Novartis Institutes of Biomedical Research, N. Hartmann Employee of: Novartis Institutes of Biomedical Research, K. Abrams Shareholder of: Novartis, Employee of: Novartis Pharmaceutical corporation, M. Gattorno Grant/research support: Novartis, SOBI, Speakers bureau: Novartis, SOBI

DOI 10.1136/annrheumdis-2014-eular.1503

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.